{"entity":{"id":"nct05319314","kind":"trial","name":"LYL273 for Patients With Relapsed or Refractory mCRC","aka":[],"tldr":"A phase 1/2 trial of LYL273 in colorectal cancer, run by Lyell Immunopharma, Inc., now recruiting.","summary":"LYL273 for Patients With Relapsed or Refractory mCRC is a phase 1/2 interventional study registered as NCT05319314 by Lyell Immunopharma, Inc., with 155 participants planned, started 2022-08-01 and due to reach its primary completion in 2028-06. Interventions recorded: LYL273.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05319314","url":"https://clinicaltrials.gov/study/NCT05319314"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lyell-immunopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05319314","phase":"1/2","setting":"A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of LYL273 in Patients With Relapsed or Refractory Metastatic Colorectal Cancer","sponsor":"Lyell Immunopharma, Inc.","enrolled":155,"outcomes":[]},"route":"/trials/nct05319314/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"company":[{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/"}]}}